Reviews
30 September 2025

Iron supplementation in heart failure and iron deficiency: does it help?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
30
Views
79
Downloads

Authors

Iron deficiency (ID) is present in 30-80% of patients with heart failure (HF) and is associated with poor prognosis. Intravenous (IV) iron therapy has been evaluated in several randomized controlled trials and consistently shown to improve functional outcomes. In FAIR-HF, 50% of patients receiving FCM achieved NYHA class improvement to I or II by 24 weeks vs 30% with placebo. CONFIRM-HF showed a significant 33-meter increase in 6-minute walk distance (6MWD) at 24 weeks (p=0.002), alongside improvements in NYHA class. The recent trial FAIR-HF2 demonstrated smaller but significant gains in 6MWD (+10.7 m) and global well-being at 12 months. Cardiovascular outcomes have been more variable. AFFIRM-AHF showed a 26% reduction in total HF hospitalizations (HR 0.74; 95% CI, 0.58-0.94) with IV iron vs placebo. Although the composite of cardiovascular death or first HF hospitalization was narrowly non-significant (HR 0.79; 95% CI, 0.62-1.01), the effect may still be clinically meaningful. IRONMAN, using ferric derisomaltose vs placebo, was neutral for the primary endpoint of HF hospitalization and cardiovascular death (RR 0.82; 95% CI, 0.66-1.02) but showed benefit in a COVID-censored sensitivity analysis (RR 0.76; 95% CI, 0.58-1.00).  In HEART-FID, involving over 3,000 patients, no benefit was also seen with IV iron for the composite of death, HF hospitalization, and 6MWD at 99% CI, however was significant at 95% CI. FAIR-HF2 showed a 21% reduction in the primary endpoint (HR 0.79; 95% CI 0.61-1.02) with IV iron, which did not meet statistical significance, but a prespecified 12-month sensitivity analysis demonstrated a 29% reduction in first cardiovascular death or HF hospitalization (0.71 (95% CI, 0.53-0.94) and a 35% reduction in total HF hospitalizations (RR 0.65; 95% CI, 0.47-0.90). The most recent meta-analysis (n>7,000) showed a 28% reduction of composite of cardiovascular death and HF hospitalizations at 1 year (RR 0.72; 95% CI, 0.55-0.89) with IV iron. Benefits were sustained at longer term follow up and were consistent across most subgroups. The totality of evidence supports IV iron in HFrEF with ID to improve symptoms and reduce HF hospitalizations, especially in the first year. Future research should explore optimal long-term dosing, sex-specific responses, and the role of IV iron in HF with preserved ejection fraction.

Altmetrics

Downloads

Download data is not yet available.

Citations

1. Rocha BML, Cunha GJL, Menezes Falcão LF. The burden of iron deficiency in heart failure. J Am Coll Cardiol 2018;71:782-93. DOI: https://doi.org/10.1016/j.jacc.2017.12.027
2. Ponikowski P, Mentz RJ, Hernandez AF, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J 2023;44:5077-91. DOI: https://doi.org/10.1093/eurheartj/ehad586
3. Aland SC, Gertler C, Bräunig HL, et al. Exercise capacity, iron deficiency and depressive symptoms in patients with asymptomatic chronic systolic heart failure. Global Cardiology 2024;2:39. DOI: https://doi.org/10.4081/cardio.2024.39
4. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726. DOI: https://doi.org/10.1093/eurheartj/ehab368
5. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol 2022;79:e263-421. DOI: https://doi.org/10.1016/j.jacc.2021.12.012
6. Talha KM, Butler J, von Haehling S, et al. Defining iron replete status in patients with heart failure treated with intravenous iron. Global Cardiology 2023;1:17. DOI: https://doi.org/10.4081/cardio.2023.17
7. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48. DOI: https://doi.org/10.1056/NEJMoa0908355
8. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657-68. DOI: https://doi.org/10.1093/eurheartj/ehu385
9. Anker SD, Friede T, Butler J, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency. JAMA 2025;333:1965-76. DOI: https://doi.org/10.1001/jama.2025.3833
10. von Haehling S, Doehner W, Evertz R, et al. Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J 2024;45:3789-800. DOI: https://doi.org/10.1093/eurheartj/ehae479
11. Cheema B, Chokshi A, Orimoloye O, Ardehali H. Intravenous iron repletion for patients with heart failure and iron deficiency. J Am Coll Cardiol 2024;83:2674-89. DOI: https://doi.org/10.1016/j.jacc.2024.03.431
12. Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency. JAMA 2017;317:1958. DOI: https://doi.org/10.1001/jama.2017.5427
13. Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020;396:1895-904. DOI: https://doi.org/10.1016/S0140-6736(20)32339-4
14. Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022;400:2199-209. DOI: https://doi.org/10.1016/S0140-6736(22)02083-9
15. Mentz RJ, Garg J, Rockhold FW, et al. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med 2023;389:975-86. DOI: https://doi.org/10.1056/NEJMoa2304968
16. Anker SD, Karakas M, Mentz RJ, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med 2025;31:2640-6. DOI: https://doi.org/10.1038/s41591-025-03671-1
17. McEwan P, Ponikowski P, Davis JA, et al. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF. Eur J Heart Fail 2021;23:1687-97. DOI: https://doi.org/10.1002/ejhf.2270
18. Packer M, Anker SD, Butler J, et al. Redefining iron deficiency in patients with chronic heart failure. Circulation 2024;150:151-61. DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.068883
19. Lindberg F, Lund LH, Benson L, et al. Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinineMeasurements collaborative project. Eur J Heart Fail 2023;25:1270-80. DOI: https://doi.org/10.1002/ejhf.2879
20. Karakas M, Friede T, Butler J, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR‐HF2 DZHK05 trial): Sex‐specific outcomes. Eur J Heart Fail 2025 Online ahead of print.

How to Cite



1.
Khan LA, Javaid SS, Butler J. Iron supplementation in heart failure and iron deficiency: does it help?. Global Cardiol [Internet]. 2025 Sep. 30 [cited 2025 Oct. 5];3(3). Available from: https://www.globalcardiology.info/site/article/view/82

Share